

October 27, 2016



# Navidea Biopharmaceuticals to Announce Third Quarter 2016 Financial Results on November 3, 2016

**- Conference call with investment community to follow at 8:30 a.m. ET -**

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that the Company will report its financial results for the third quarter of 2016, on Thursday, November 3, 2016 prior to a conference call with the investment community scheduled at 8:30 a.m. ET.

Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, <http://ir.navidea.com>, approximately two to four hours after the live event.

Event: Navidea Biopharmaceuticals Q3 2016 Financial Results Conference Call  
Date/Time: November 3, 2016; 8:30 a.m. ET

Webcast Link: <http://edge.media-server.com/m/p/on2557gm/lan/en>

Dial-in Number – US: (855) 897-5884

Dial in Number – Int'l: (720) 634-2940

Conference ID  
Number: 3723903

Replay: A webcast replay will be available on the Investor Relations section of our website at <http://ir.navidea.com> for 30 days.

## About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. [Lymphoseek](#)® (technetium Tc 99m tilmanocept) injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. The development activities of the Manocept immunotherapeutic platform will be conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts. For more information,

please visit [www.navidea.com](http://www.navidea.com).

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20161027005498/en/>

Navidea Biopharmaceuticals

Investors & Media

Sharon Correia, 978-655-2686

Senior Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.